0001209191-20-060362.txt : 20201124
0001209191-20-060362.hdr.sgml : 20201124
20201124191250
ACCESSION NUMBER: 0001209191-20-060362
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201120
FILED AS OF DATE: 20201124
DATE AS OF CHANGE: 20201124
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kayitalire Louis
CENTRAL INDEX KEY: 0001831519
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37718
FILM NUMBER: 201346276
MAIL ADDRESS:
STREET 1: C/O EDDEVA B920
STREET 2: BABRAHAM RESEARCH CAMPUS
CITY: CAMBRIDGE
STATE: X0
ZIP: CB22 3AT
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: F-star Therapeutics, Inc.
CENTRAL INDEX KEY: 0001566373
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 522386345
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 35 PARKWOOD DRIVE
STREET 2: BABRAHAM RESEARCH CAMPUS
CITY: CAMBRIDGE
STATE: X0
ZIP: CB22 3AT
BUSINESS PHONE: 44 1223 497400
MAIL ADDRESS:
STREET 1: 35 PARKWOOD DRIVE
STREET 2: BABRAHAM RESEARCH CAMPUS
CITY: CAMBRIDGE
STATE: X0
ZIP: CB22 3AT
FORMER COMPANY:
FORMER CONFORMED NAME: Spring Bank Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20130108
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-11-20
0
0001566373
F-star Therapeutics, Inc.
FSTX
0001831519
Kayitalire Louis
C/O F-STAR THERAPEUTICS, INC.
EDDEVA B920, BABRAHAM RESEARCH CAMPUS
CAMBRIDGE
X0
CB22 3AT
UNITED KINGDOM
0
1
0
0
Chief Medical Officer
Stock Option (right to buy)
16.62
2020-11-20
4
A
0
27289
0.00
A
2029-06-17
Common Stock
27289
27289
D
Restricted Stock Units
2020-11-20
4
A
0
26437
0.00
A
Common Stock
26437
26437
D
This option was issued in replacement of an option to purchase shares of F-star Therapeutics Limited.
28% of the options shall vest on the first anniversary of the commencement of employment of the option holder and 2% on the last day of each month subsequent to such first anniversary until the option is fully vested on the fourth anniversary from commencement of employment.
Each restricted stock unit represents a contingent right to receive one share of common stock.
Twenty-five per cent (25%) of the total number of Shares under Award shall vest on the first anniversary of the Vesting Commencement Date, July 1, 2020, and two and one twelfth per cent (2.083%) of the total number of Shares under Award shall vest monthly thereafter, provided in each case that the Participant remains a Service Provider continuously from the Vesting Commencement Date to the relevant date.
/s/ Darlene Deptula-Hicks, Attorney-in-fact
2020-11-24